

Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies

Boehringer Ingelheim

MONROVIA, Calif., USA and INGELHEIM, Germany - February 21th, 2012 – Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies. Under the terms of the agreement, Boehringer Ingelheim will provide all manufacturing and product supply from preclinical through Phase 1 development. Xencor is responsible for preclinical and clinical studies and retains all development and commercial rights to products under the agreement. Upon successful advancement of clinical programs beyond Phase 1 development, Boehringer Ingelheim has certain manufacturing rights to supply clinical and commercial material to Xencor.

[SOURCE](#) [1]

Source URL (retrieved on 01/27/2015 - 9:52am):

<http://www.chem.info/news/2012/02/boehringer-ingelheim-and-xencor-enter-collaboration-agreement-development-manufacture-and-supply-biosuperior-monoclonal-antibodies>

Links:

[1] http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/21_february_2012xencor.html